Aviva PLC Decreases Stock Position in Zoetis Inc. $ZTS

Aviva PLC lowered its stake in Zoetis Inc. (NYSE:ZTS) by 5.8% during the 4th quarter, Holdings Channel reports. The firm owned 934,005 shares of the company’s stock after selling 57,246 shares during the quarter. Aviva PLC’s holdings in Zoetis were worth $117,517,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ZTS. Global Wealth Strategies & Associates purchased a new stake in Zoetis in the 4th quarter worth $25,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis in the 4th quarter worth $30,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis in the 3rd quarter worth $31,000. Holos Integrated Wealth LLC purchased a new stake in Zoetis in the 4th quarter worth $32,000. Finally, Elyxium Wealth LLC purchased a new stake in Zoetis in the 4th quarter worth $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a research note on Friday, May 15th. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, UBS Group reduced their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Six analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $133.92.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $81.51 on Friday. The company has a market capitalization of $34.17 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 1.27 and a beta of 0.75. Zoetis Inc. has a 12 month low of $72.38 and a 12 month high of $168.83. The firm’s 50-day moving average is $97.70 and its 200 day moving average is $114.47. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts predict that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio is presently 35.16%.

Insider Activity at Zoetis

In other news, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Bisaro purchased 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
• Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
• Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
• Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.